Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOV1601 in solid organ malignancies
NCT04014257Phase 1Completed
- Sponsor
- Handok
- Start
- Aug 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CHC2014 in solid tumor (2 arms), sponsored by Handok. Primary endpoint: Recommended Phase 2 Dose or Maximum Tolerated Dose. Started Aug 2019; status: completed.
02
Drugs
CHC2014
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04014257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04014257.